GlassScriptPhysician profile
April Coughlan
NPI 1710373667
$4,783.97
in general payments reported to CMS, 2019-2025
46 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $786 · 2022: $1,410 · 2023: $1,473 · 2024: $962 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,340 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,339.89 |
| Education | $247.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $456.51 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $435.26 | 2021-2025 | |
| Janssen Biotech, INC. | $371.88 | 2021-2025 | Imbruvica, Talvey, Tecvayli |
| Jazz Pharmaceuticals INC. | $320.32 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $273.55 | 2021-2024 | Opdivo, Reblozyl |
| Merck Sharp & Dohme LLC | $242.72 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $230.21 | 2023-2024 | Enhertu, Imfinzi, Tagrisso |
| Novartis Pharmaceuticals Corporation | $228.37 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $227.79 | 2021-2023 | Epkinly, Imbruvica |
| Seagen INC. | $180.76 | 2021-2023 | Tukysa |
| Celgene Corporation | $135.02 | 2021-2024 | Pomalyst, Opdualag, Reblozyl |
| Amgen INC. | $126.49 | 2021-2023 | Kyprolis, Prolia, Evenity |
| Daiichi Sankyo INC. | $117.93 | 2021-2024 | Enhertu |
| Abbvie INC. | $111.53 | 2024-2025 | |
| Eisai INC. | $105.42 | 2022-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Coughlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.